Business
ANGLE announce Tri-Con presentation with BioView
ANGLE announce Tri-Con presentation with BioView.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n RNS Number : 9730D\n Angle PLC\n 25 February 2020\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 25 February 2020\n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n ANGLE and BioView to Present Combined Solution for Circulating Tumor Cell Detection and Analysis at Molecular Med Tri-Con 2020 in San Francisco, 4 March 2020\n \n \n \n \n \n \n \n \n ANGLE plc, (AIM:AGL OTCQX:ANPCY) a world leading liquid biopsy company, and BioView Ltd. (TASE:BIOV), a provider of automated cell imaging and analysis solutions, announced today that they will present results of their recent collaboration to develop an integrated workflow for identifying clinical biomarkers on circulating tumor cells (CTCs) at the Molecular Med Tri-Con 2020 Conference in San Francisco (Tri-Con) on March 4, 2020. \n \n \n \n \n \n The collaboration combines ANGLE's Parsortix system, which enables a liquid biopsy (a simple blood test) to be used to provide the cancer cells for analysis in a format suitable for multiple subsequent downstream analyses, and BioView's Duet imaging and analysis system, which provides all essential functions required to transform resource-heavy manual CTC detection and analysis into an automated, high-throughput, high-capacity process that is suited to clinical practice. Through the collaboration, ANGLE and BioView are integrating their best-in-class technologies to create a workflow for the isolation and characterisation of CTCs with the goal of providing clinical insights to physicians such as the expression of HER-2 (in relation to the drug Herceptin) and PD-L1 (in relation to immunotherapy drugs).\n \n \n \n \n \n The presentation, \"Combining Cell Harvesting and Imaging Technologies for CTC Liquid Biopsy Sample-to-Answer\", will be presented by Anne-Sophie Pailhes-Jimenez, ANGLE Senior R&D Group Leader at Molecular Med Tri-Con 2020. \n \n \n \n \n \n The Tri-Con Conference is a leading industry event in the personalised medicine space. The upcoming event will focus on emerging therapeutic, diagnostic, and technology approaches to advance precision medicine. The presentation will take place at 12.25 on March 4 in the Muscone South Convention Centre, San Francisco. \n \n \n \n \n \n ANGLE's Parsortix system and BioView'...